Business
Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit
Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCBB:SVON), a \n biopharmaceutical company which discovers, develops and acquires \n next-generation biologics for the treatment of cancer and immunological \n diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief \n Scientific Officer, will give an invited oral presentation entitled “Engineering \n Cow Antibodies with Ultralong CDRs” at the GTC Protein Discovery \n Summit conference in Boston, MA on October 22, 2015. “Antibodies with \n unique features, such as long target binding regions, are becoming more \n important in drug discovery. Our unique humanized cow scaffold has \n potential to address many challenging targets like ion channels,” noted \n Dr. Smider. “The discovery of the structural and genetic features of cow \n antibodies were featured in the journal Cell just two years ago, \n and we are excited to share our progress in engineering these exciting \n next-generation antibodies for therapeutics.”\n \n \n About Sevion Therapeutics\n \n \n Sevion Therapeutics is a biopharmaceutical company building and \n developing a portfolio of innovative therapeutics, from both internal \n discovery and acquisition, for the treatment of cancer and immunological \n diseases. The Company’s product candidates are derived from multiple key \n proprietary technology platforms: cell-based arrayed antibody discovery, \n ultralong antibody scaffolds and Chimerasome nanocages. Sevion has \n leveraged these technologies to build a pipeline of innovative product \n candidates. For more information, please visit SevionTherapeutics.com.\n \n \n Forward-Looking Statements\n \n \n Certain statements included in this press release are forward-looking \n statements within the meaning of the Private Securities Litigation \n Reform Act of 1995. Actual results could differ materially from such \n statements expressed or implied herein as a result of a variety of \n factors, including, but not limited to: the Company’s ability to \n continue as a going concern; the ability of the Company to consummate \n additional financings; the development of the Company’s antibody \n technology; the approval of the Company’s patent applications; the \n Company’s ability to successfully defend its inte...